Ultragenyx Pharmaceutical Inc. (RARE)
NASDAQ: RARE · Real-Time Price · USD
41.28
+1.28 (3.20%)
Jan 21, 2025, 4:00 PM EST - Market closed
Ultragenyx Pharmaceutical Revenue
Ultragenyx Pharmaceutical had revenue of $139.49M in the quarter ending September 30, 2024, with 42.27% growth. This brings the company's revenue in the last twelve months to $522.75M, up 27.44% year-over-year. In the year 2023, Ultragenyx Pharmaceutical had annual revenue of $434.25M with 19.52% growth.
Revenue (ttm)
$522.75M
Revenue Growth
+27.44%
P/S Ratio
6.86
Revenue / Employee
$409,675
Employees
1,276
Market Cap
3.81B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 434.25M | 70.92M | 19.52% |
Dec 31, 2022 | 363.33M | 11.92M | 3.39% |
Dec 31, 2021 | 351.41M | 80.38M | 29.66% |
Dec 31, 2020 | 271.03M | 167.32M | 161.32% |
Dec 31, 2019 | 103.71M | 52.22M | 101.41% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 87.70B |
Merck & Co. | 63.17B |
AbbVie | 55.53B |
AstraZeneca | 51.21B |
Novartis AG | 49.94B |
Thermo Fisher Scientific | 42.37B |
Abbott Laboratories | 41.22B |
RARE News
- 4 days ago - Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 6 days ago - Ultragenyx's Multiple Commercial Assets And Candidates Impress Analyst; Sees Solid Upside - Benzinga
- 9 days ago - Ultragenyx Reports Preliminary 2024 Revenue, Financial Guidance for 2025, Pipeline Updates, and 2025 Milestones - GlobeNewsWire
- 15 days ago - Ultragenyx to Present at the 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 15 days ago - European Commission (EC) Extends the Approval of Evkeeza® (evinacumab) to Children as Young as 6-months Old with Homozygous Familial Hypercholesterolemia (HoFH) - GlobeNewsWire
- 4 weeks ago - NHS England Rolls Out Evkeeza® ▼(evinacumab) for Eligible Adults and Adolescents Aged 12 Years and Older with Homozygous Familial Hypercholesterolaemia (HoFH) - GlobeNewsWire
- 4 weeks ago - Ultragenyx Announces First Patient Dosed in Pivotal Phase 3 Aspire Study Evaluating GTX-102 in Angelman Syndrome - GlobeNewsWire
- 2 months ago - Ultragenyx to Participate in Investor Conferences in December - GlobeNewsWire